XML 78 R5.htm IDEA: XBRL DOCUMENT v3.20.1
Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)
Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Beginning balance, shares at Jun. 30, 2018 0 1,794,762      
Beginning balance, amount at Jun. 30, 2018 $ 0 $ 179 $ 92,681,918 $ (79,257,592) $ 13,424,505
Stock-based compensation, amount     152,114   152,114
Adjustment for rounding of shares due to stock split, shares   6,649      
Adjustment for rounding of shares due to stock split, amount   $ 1 (1)   0
Net loss (3,446,483) (3,446,483)
Ending balance, shares at Sep. 30, 2018 0 1,801,411      
Ending balance, amount at Sep. 30, 2018 $ 0 $ 180 92,834,031 (82,704,075) 10,130,136
Beginning balance, shares at Jun. 30, 2018 0 1,794,762      
Beginning balance, amount at Jun. 30, 2018 $ 0 $ 179 92,681,918 (79,257,592) 13,424,505
Cashless warrant exercise, amount         0
Net loss         (12,600,007)
Ending balance, shares at Mar. 31, 2019 2,335,665 12,848,499      
Ending balance, amount at Mar. 31, 2019 $ 234 $ 1,287 107,893,259 (91,857,599) 16,037,179
Beginning balance, shares at Sep. 30, 2018 0 1,801,411      
Beginning balance, amount at Sep. 30, 2018 $ 0 $ 180 92,834,031 (82,704,075) 10,130,136
Stock-based compensation, shares   2,707,022      
Stock-based compensation, amount   $ 270 193,792   194,062
Common stock issued to employee, shares   9,000      
Common stock issued to employee, amount   $ 1 11,689   11,690
Issuance of preferred and common stock, net of cash issuance costs, shares 8,342,993 1,777,007      
Issuance of preferred and common stock, net of cash issuance costs, amount $ 834 $ 178 11,810,373   11,811,385
Warrants issued in connection with the registered offering     1,827,628   1,827,628
Warrants issued in connection with the registered offering to the placement agents, non-cash issuance costs     61,024   61,024
Preferred stocks issued in connection with the purchase of assets, shares 400,000        
Preferred stocks issued in connection with the purchase of assets, amount $ 40   519,560   519,600
Preferred stock converted into common stock, shares (4,210,329) 4,210,329      
Preferred stock converted into common stock, amount $ (421) $ 421     0
Net loss (4,657,662) (4,657,662)
Ending balance, shares at Dec. 31, 2018 4,532,664 10,504,769      
Ending balance, amount at Dec. 31, 2018 $ 453 $ 1,050 107,258,097 (87,361,737) 19,897,863
Stock-based compensation, shares   (25,600)      
Stock-based compensation, amount   $ (2) 376,668   376,666
Preferred stock converted into common stock, shares (2,196,999) 2,196,999      
Preferred stock converted into common stock, amount $ (219) $ 219     0
Warrant exercises, shares   172,331      
Warrant exercises, amount   $ 17 258,495   258,512
Net loss (4,495,862) (4,495,862)
Ending balance, shares at Mar. 31, 2019 2,335,665 12,848,499      
Ending balance, amount at Mar. 31, 2019 $ 234 $ 1,287 107,893,259 (91,857,599) 16,037,179
Beginning balance, shares at Jun. 30, 2019 3,594,981 17,538,071      
Beginning balance, amount at Jun. 30, 2019 $ 359 $ 1,754 113,475,205 (106,389,500) 7,087,818
Stock-based compensation, amount     165,171   165,171
Preferred stock converted into common stock, shares (443,833) 443,833      
Preferred stock converted into common stock, amount $ (44) $ 44     0
Net loss (4,929,030) (4,929,030)
Ending balance, shares at Sep. 30, 2019 3,151,148 17,981,904      
Ending balance, amount at Sep. 30, 2019 $ 315 $ 1,798 113,640,376 (111,318,530) 2,323,959
Beginning balance, shares at Jun. 30, 2019 3,594,981 17,538,071      
Beginning balance, amount at Jun. 30, 2019 $ 359 $ 1,754 113,475,205 (106,389,500) 7,087,818
Cashless warrant exercise, amount         792
Net loss         (10,475,582)
Ending balance, shares at Mar. 31, 2020 9,805,845 100,610,380      
Ending balance, amount at Mar. 31, 2020 $ 981 $ 10,061 202,557,856 (116,865,082) 85,703,816
Beginning balance, shares at Sep. 30, 2019 3,151,148 17,981,904      
Beginning balance, amount at Sep. 30, 2019 $ 315 $ 1,798 113,640,376 (111,318,530) 2,323,959
Stock-based compensation, amount     162,264   162,264
Issuance of Series F preferred stock from October 2019 private placement financing, net, shares 10,000        
Issuance of Series F preferred stock from October 2019 private placement financing, net, amount $ 1   5,249,483   5,249,484
Warrants issued in connection with the private placement     4,008,866   4,008,866
Issuance of Series G preferred stock due to acquisition of the Cerecor Portfolio of Pediatrics Therapeutics, shares 9,805,845        
Issuance of Series G preferred stock due to acquisition of the Cerecor Portfolio of Pediatrics Therapeutics, amount $ 981   5,558,933   5,559,914
Preferred stock converted into common stock, shares (2,751,148) 2,751,148      
Preferred stock converted into common stock, amount $ (275) $ 275     0
Net loss (214,247) (214,247)
Ending balance, shares at Dec. 31, 2019 10,215,845 20,733,052      
Ending balance, amount at Dec. 31, 2019 $ 1,022 $ 2,073 128,619,922 (111,532,777) 17,090,240
Stock-based compensation, shares   1,067,912      
Stock-based compensation, amount   $ 107 263,284   263,391
Cashless warrant exercise, shares   7,915,770      
Cashless warrant exercise, amount   $ 792 (792)   0
Issuance of preferred and common stock, net of cash issuance costs, shares   36,365,274      
Issuance of preferred and common stock, net of cash issuance costs, amount   $ 3,637 33,275,119   33,278,756
Warrants issued in connection with the registered offering     9,723,161   9,723,161
Warrants issued in connection with the registered offering to the placement agents, non-cash issuance costs     1,458,973   1,458,973
Issuance of Series H preferred stock and common stock due to acquisition of Innovus, shares 1,997,902 3,809,712      
Issuance of Series H preferred stock and common stock due to acquisition of Innovus, amount $ 200 $ 381 4,405,603   4,406,184
Preferred stock converted into common stock, shares (2,407,902) 12,397,902      
Preferred stock converted into common stock, amount $ (241) $ 1,240 91,881   92,880
Warrant exercises, shares   17,082,994      
Warrant exercises, amount   $ 1,708 22,987,958   22,989,666
CVR payouts, shares   1,237,764      
CVR payouts, amount   $ 123 1,732,747   1,732,870
Net loss (5,332,305) (5,332,305)
Ending balance, shares at Mar. 31, 2020 9,805,845 100,610,380      
Ending balance, amount at Mar. 31, 2020 $ 981 $ 10,061 $ 202,557,856 $ (116,865,082) $ 85,703,816